Theragen Bio (CEO Hwang Tae-soon), a global genome analysis service and AI-based new drug development company, announced on the 7th that it has completed the acquisition of a patent for ‘DeepOmics Marker™’, an AI-based patient classification molecular subtype calculation device.
The official name of the patent is ‘Molecular subtype calculation device, method for calculating the number of molecular subtypes for diseases, and computer program for executing the method DeepOmics Marker™’. The goal is to use a deep learning-based program to effectively classify patients and derive key markers for each detailed subtype of disease to find customized drugs or new drug development targets for each patient. The company has so far obtained two patents for DeepOmics Marker™ and three patents for DeepOmics Neo™. In the future, Theragen Bio plans to develop customized treatment targets and new drugs for each patient through patent applications for the genome big data service ‘DeepOmics™’ and detailed services.
‘DeepOmics Marker™ ‘ , unlike existing analysis methods, is a groundbreaking method that analyzes the difference in expression rank between genes in each sample compared to normal, enabling more accurate disease classification than existing methods. In addition, by automatically discovering molecular subtypes among disease cohorts, it has become possible to discover molecular subtypes of diseases that were difficult to classify by existing methods. In particular, as a result of a large-scale breast cancer cohort analysis, DeepOmics Marker™ was able to distinguish patients with poor prognosis among patients with the Luminal A molecular subtype, which are classified as low-risk by existing molecular subtyping methods, and its excellent performance was verified.
The genomic big data service ‘DeepOmics™’ is an AI-based patient-specific diagnosis and prognosis analysis platform being developed by Theragen Bio. ‘DeepOmics Neo™’, a platform for anti-cancer vaccine research and development, and ‘DeepOmics Marker™’, a platform that analyzes symptoms and prognosis before accompanying diagnosis for each individual patient. It consists of ‘DeepOmics Network™’, which analyzes the effects of drugs on patients, and ‘DeepOmics Target™’, which selects effective therapeutic drug targets.
Taesoon Hwang, CEO of Theragen Bio, said, “If we apply DeepOmics Marker™ to each patient and classify them into detailed molecular subtypes, we can predict each individual’s responsiveness to existing drugs. In particular, we can discover therapeutic targets for malignant molecular subtypes for which there are currently no treatments and develop new drugs. “We expect to be able to provide a basis for development,” he said. “From diagnosis to prognosis prediction, customized treatment, and discovery of new treatment targets through patient classification, development of diagnostic markers, and treatment for diseases for which there is no existing classification system.” “We will complete an AI-based total genome analysis platform,” he said.
Meanwhile, Theragen Bio operates on the principle of eliminating cancer cells by activating the immune system in vivo by administering customized antigens predicted through cancer genome analysis in the form of messenger ribonucleic acid (mRNA), peptides (amino acid conjugates), and dendritic cells. A personalized anti-cancer vaccine is being developed. Theragen Bio is a leading genome analysis company in Korea. Since its spin-off from Theragen Etex in May 2020, it has been expanding its business to the development of personalized cancer vaccines, targeted treatment for rectal cancer, BI platform development, and AI medical big data. .
Source: Pangyo Techno Valley Official Newsroom
→ Go to ‘Asia Innovation Hub Pangyo Techno Valley 2021’ news